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Abstract 
The ATP-dependent ransport of the three 3H-labeled, amphiphilic cations quinidine, N-(n-pentyl)-quinidinium, and N-(4’,4’-azo-n-pentyl)-21- 
deoxyajmalinium was studied in rat canalicular plasma membrane vesicles. N-Alkylation of quinidine with an n-pentyl residue resulted in a 
permanently charged cationic substrate for ATP-dependent ransport which exhibited a IO-fold higher transport rate relative to quinidine. The K, 
value was 0.4 PM for N-(n-pentyl)-quinidinium and 5 PM for quinidine. The permanently cationic and photolabile derivative of ajmaline, N-(4’,4’- 
azo-n-pentyl)-21-deoxyajmalinium, wasalso an efficient substrate and served to label canalicular membrane proteins with molecular masses of 143 
kDa and 108 kDa. ATP-dependent ransport of the permanently charged amphiphilic cations was inhibited by the P-glycoprotein inhibitors and 
substrates quinidine, verapamil, and daunorubicin. The data demonstrate that N-alkylation of quinidine and ajmaline results in most efficient 
substrates for mdrl P-glycoprotein-mediated ATP-dependent ransport. 
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1. Introduction 
The multidrug resistance (MDR) phenomenon is often 
associated with the expression of multidrug resistance 
(mdr) genes encoding a family of integral membrane 
glycoproteins known as P-glycoproteins [11. These trans- 
port proteins bind various hydrophobic, mostly basic 
drugs and chemotherapeutic agents and pump them out 
of the cell by an ATP-dependent process [ 11. P-glycopro- 
teins are also expressed in normal tissues such as kidney, 
adrenals, and liver [24]. In rat liver canalicular mem- 
branes the P-glycoprotein-mediated ATP-dependent 
transport has been detected by the accumulation of the 
substrates daunorubicin and vinblastine in inside-out 
oriented vesicles [2,5,6]. In this report we demonstrate 
the substrate properties for P-glycoprotein-mediated 
ATP-dependent ransport of quinidine and the two per- 
manently cationic quinuclidinyl compounds APD-ajmal- 
inium and N-(n-pentyl)-quinidinium. The latter com- 
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pound exhibited the highest affinity for ATP-dependent 
transport of amphiphilic cations known at present. 
These N-alkylated substrates may serve in future studies 
to characterize the function of m&l gene products in 
normal and malignant cells. 
2. Materials and methods 
2.1. Materials 
ATP (Tris-salt), S-AMP (free acid), adenylyl(a$-methylene)- 
diphosphonate (AMPPCP), potassium creatine phosphate, taurocho- 
late, verapamil, daunorubicin, quinidine, and sodium vanadate were 
purchased from Sigma Chemical Co., St. Louis, MO, USA. I-Iodopen- 
tane, 9-fluorenone, and potassium tert-butylate in tetrahydrofuran 
were from Aldrich, Steinheim, Germany. Creatine kinase was from 
Boehringer Mannheim, Mannheim, Germany. [‘HlTaurocholate (77.7 
GBq/mmol) and sodium borohydride (503.2 GBq/mmol) were from 
DuPont-New England Nuclear, Boston, MA, USA. 1-Pentyl quinu- 
clidinium iodide was synthesized by alkylation of quinidine with I- 
iodopentane in oxygen-free acetone according to [7]. N-(4’,4’-azo-n- 
pentyl)-21-deoxy-[21-‘Hlajmalinium [8] (46 GBq/mmol) was synthe- 
sized as described [9%12] and kindly provided by Prof. G. Kurz, Univer- 
sity of Freiburg, Germany. Nitrocellulose filters (pore size 0.2pm) were 
from Schleicher and Schiill, Dassel, Germany. Glass microfibre filters 
(type GFIF; pore size 2 0.7 pm) were purchased from Whatman Inter- 
national Ltd., Maidstone, UK. Scintillation fluid (Filter Count) was 
from Canberra Packard, Warrenville, IL, USA. All other chemicals 
were of analytical grade. 
2.2. Animals 
For preparations enriched in canalicular membranes, male Wistar 
rats (200-250 g), from the Zentralinstitut fiir Versuchstierzucht, 
Hannover, Germany, were employed. Mutant male Wistar rats with 
hepatobiliary transport defect (TR- or GY) [13,14] were from Dr. F. 
Kuipers (University of Groningen, The Netherlands). Animals were 
maintained on a standard diet with free access to food and water. 
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2.3. Preparation and characterization of membranes 
Membrane fractions enriched in the hepatocyte canalicular mem- 
brane domain were prepared from rat liver and characterized as de- 
scribed [15,16]. 
2.4. Synthesis of I-(n-pentyl)-9-[“H]quinidinium 
Quinidine was oxidized to quinidinone (Poxo-quinidine) using po- 
tassium tert-butylate and 9-fluorenone in tetrahydrofuran according to 
[17]. The product was purified using thin-layer chromatography plates 
silica gel 60 (E. Merck, Darmstadt, Germany) with methanol/ethyl 
acetate/cyclohexane/acetic acid (40 : 40 : 16 : 2, v/v/v/v) as solvent. The 
relative retention of quinidinone was 0.14 compared to 0.36 for quini- 
dine. The compound with a characteristic UV-absorption at 360 nm 
was extracted from the silica gel with methanol and subsequently re- 
duced by sodium [‘Hlborohydride (503 GBq/mmol) in methanol/O.01 
M NaOH (50: 50, v/v). Purification of 9-[‘Hlquinidine was performed 
by RP-HPLC on a Cl8 Hypersil column (4.6 mm x 250 mm, 5 pm 
particles; Shandon, Runcom, UK) with a Cl8 precolumn (Waters, 
Milford, MA, USA) using acetonitril/methanol/water/acetic acid 
(54: 14: 28: 1, v/v/v/v; pH 5.4, adjusted with ammonium hydroxide) as 
the mobile-phase system. The flow rate was 0.75 ml/min. Alkylation of 
[P3H]quinidine with I-iodopentane in acetone [7] resulted in l-(n- 
pentyl)-[9-3H]quinidinium which was again purified by the same RP- 
HPLC system as described above. The identity of the compound was 
confirmed by comigration of the non labeled n-pentyl quinidinium 
iodide. The purity of the ‘H-labeled substrates used for the kinetic 
experiments was 295%. 
2.5. Vesicle transport studies 
Transport of [3H]taurocholate was measured by a rapid filtration 
technique using nitrocellulose filters (0.2pm pore size) presoaked in 250 
mM sucrose and 10 mM Tris-HCl (pH 7.4). The filtration was per- 
formed at 200 mbar pressure. Transport of ‘H-labeled APD-ajmalin- 
ium, quinidine, and pentyl quinidinium, respectively, was measured by 
the same technique using glass microfibre filters (pore size 2 0.7 pm) 
presoaked in Tris-buffered saline (pH 7.4). This filtration was per- 
formed at 850 mbar pressure. 
2.6. Measurement of ATP-dependent transport into canalicular 
membrane vesicles 
Membrane vesicles were incubated in the presence of 4 mM ATP, 10 
mM MgCl,, 10 mM creatine phosphate, 100 &ml creatine kinase, 250 
mM sucrose, 10 mM Tris-HCl (pH 7.4) and the labeled substrate at a 
final volume of 110 ~1. 20 ~1 samples were taken at the indicated time 
points and diluted in 1 ml of ice-cold Tris-buffered saline (pH 7.4). This 
solution was applied to the pre-soaked filters and rinsed with 5 ml of 
ice-cold Tris-buffered saline (pH 7.4) containing 0.05% Tween and with 
10 ml of Tris-buffered saline (pH 7.4). In control experiments ATP was 
replaced by 5’-AMP. Transport rates were calculated by subtracting the 
values in the presence of 5’-AMP from those in the presence of ATP. 
2.7. Photoaffinity labeling and SDS-PAGE 
Canalicular membrane vesicles (50 g protein) were incubated with 
APD-ajmalinium (185 KBq) at 37°C for 10 min and subsequently 
irradiated at 350 nm for 10 min at 4°C. After irradiation labeled pro- 
teins were separated by SDS-PAGE (7.5% gel, unboiled samples). In- 
corporated radioactivity was determined as described [8,15]. 
3. Results 
3.1. ATP-dependent ransport of organic cations in rat 
liver canalicular membrane vesicles 
ATP-dependent transport of three different cationic 
compounds was observed using highly enriched rat liver 
CMV. [3H]Quinidine (Fig. l), N-(n-pentyl)-[3H]quinidin- 
ium (Fig. 2), and APD-[3H]ajmalinium (Fig. 3) exhibited 
ATP-dependent linear uptake into inside-out CMV in 
the presence of ATP and a regenerating system. Identical 
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Fig. 1. ATP-dependent ransport of [‘Hlquinidine into rat liver canali- 
cular membrane vesicles. Membrane vesicles (30 ,ug of protein) were 
incubated with 3H-labeled quinidine (5pM) at 37°C; 20~1 aliquots were 
removed and [‘Hlquinidine uptake was determined by the rapid filtra- 
tion technique described in section 2. Data are expressed as the mean 
+ S.E.M. from 4 separate xperiments. ATP-dependent ransport was 
calculated from the difference of [3H]quinidine incorporated in the 
presence of ATP and 5’-AMP. 
values for binding of N-(n-pentyl)-[3H]quinidinium and 
APD-[3H]ajmalinium were obtained in the presence of 
5’-AMP or the non-hydrolyzable ATP analog adenylyl- 
(j3,y-methylene)-diphosphonate indicating that ATP hy- 
drolysis is required for transport. The monoquaternary 
cations were more efficiently transported than the non- 
alkylated quinidine as evidenced by the lo-fold (for pen- 
tyl quinidinium) to 15-fold (for APD-ajmalinium) higher 
transport rates. The non-ATP-dependent binding was 
lowest for pentyl quinidinium which also exhibited the 
lowest K, value of the 3 organic cations investigated 
(Table 1). Furthermore, the efficiency of the ATP- 
dependent transport of quinidine, pentyl quinidi- 
nium, and APD-ajmalinium, calculated by the V,,,IK,,, 
ratio (Table l), amounted to 5, 450, and 77 
(ml x mg-’ x min-‘), respectively. 
Using liver CMV from transport mutant rat liver (TR- 
or GY), the rates of ATP-dependent transport of both 
cations, APD-ajmalinium (5 PM) and pentyl quinidin- 
ium (1 PM), were similar as the transport rates 
using CMV from normal Wistar rats (153 f 10 
pmol x min-’ x mg protein-’ (85% of normal) and 
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Fig. 2. ATP-dependent ransport of ‘H-labeled N-(n-pentyl)-quinidin- 
ium (5 PM) into canalicular membrane vesicles. Incubation conditions 
were the same as described in the legend to Fig. 1. Each point represents 
the mean from 4 separate xperiments. 
115 + 5 pm01 x min-’ x mg protein-’ (94% of normal), 
respectively). 
3.2. Photoaffinity labeling of rat liver canalicular 
membranes 
Photoaffinity labeling of CMV from rat liver with the 
photolabile ajmalinium derivative revealed a predomi- 
nant labeling of proteins with apparent molecular masses 
of 143 and 108 kDa (Fig. 4). 
3.3. SpeciJicity of ATP-dependent transport of 
amphiphilic cations 
Vanadate inhibited the ATP-dependent transport of 
both permanently charged organic cations with a half 
Table 1 
Kinetic parameters of the ATP-dependent ransport of amphiphilic 
cations in hepatocyte canalicular membrane vesicles 
Substrate V mm 
(pm01 fmg-’ . min-‘) ZM) 
Quinidine 25 5 
Pentyl quinidinium 180 0.4 
APD-ajmalinium 770 10 
The kinetic constants were derived from double reciprocal plots accord- 
ing to Lineweaver and Burk. Transport studies were performed as 
described in section 2. Values are from quadruplicate determinations 
with all standard deviations below 15% of the mean. 
maximal concentration of 20-30 ,uM. The ATP-depend- 
ent transport of pentyl quinidinium and APD-ajmalin- 
ium was inhibited to a similar extent by various organic 
cations known to interact with mdrl P-glycoprotein 
(Table 2). As an exception, daunorubicin inhibited the 
ATP-dependent APD-ajmalinium transport more effi- 
ciently than the transport of pentyl quinidinium. In con- 
trast, no significant inhibition of ATP-dependent auro- 
cholate transport was observed in the presence of several 
cationic inhibitors (Table 2). 
4. Discussion 
4.1. ATP-dependent transport of amphiphilic cations into 
canalicular membrane vesicles mediated by mdr 1 
P-glycoprotein 
The liver plays a central role in the disposition of 
exogenous and endogenous compounds [ 18,191. Pri- 
mary-active ATP-dependent transport is the major 
mechanism to secrete toxic and non-toxic, exogenous as 
well as endogenous ubstances across the hepatocyte ca- 
nalicular membrane into bile [4,6,15,19-231. Four dis- 
tinct ATP-dependent carriers were so far described in 
this membrane domain [2-6,19-241: (i) the ATP-driven 
bile salt export carrier (BSEC) [15,20-221, (ii) the ATP- 
dependent leukotriene export carrier (LTEC) which 
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Fig. 3. ATP-dependent uptake of ‘H-labeled APD-ajmalinium (APDA) 
(5 PM) into canalicular membrane vesicles. Incubation conditions were 
the same as described in the legend to Fig. 1. Each point represents the 
mean from 4 separate xperiments. 
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Fig. 4. Photoaffiity labeling of rat liver canalicular membranes with 
‘H-labeled APD-ajmalinium (APDA). CMV (50 ,ug) were incubated 
with ‘H-labeled APD-ajmalinium (185 kBq) for 10 min. Photoaffinity 
labeling and SDS-PAGE (7.5% gel, unboiled samples) were performed 
as described in section 2. The curve shows the radioactivity in the gel 
slices. The lane above the curve indicates the proteins reacting with the 
C219 antibody in the Western blot. The upper lane shows the Coomas- 
sie-stained gel with the molecular weight standards at the top. 
transports leukotriene C4 and related conjugates of vari- 
ous exogenous and endogenous ubstances [23], (iii) the 
ATP-dependent daunorubicin transport mediated by 
mdrl P-glycoprotein (multidrug export carrier, MDEC) 
[2-6], which was established in analogy to its function in 
multidrug-resistant umor cells, although endogenous 
substrates for this export carrier have so far not been 
clearly defined, and (iv) the mdr2 P-glycoprotein which 
plays an essential role in the secretion of phospholipids 
into bile as evidenced recently by mdr2 gene knockout in 
mice [24]. 
Substrates for mdrl P-glycoprotein can differ in their 
chemical structure and in their physicochemical proper- 
ties. Many of them contain cationic charges at the pH of 
body fluids but are not permanently charged. The so- 
dium channel blocker quinidine is an anti-arrhythmic 
agent known for a long time [25]. This drug and its 
stereoisomer quinine are both, like the calcium channel 
blocker verapamil, potent multidrug reversal agents [26 
291. Another antiarrhythmic agent, ajmaline [25], is also 
potent as multidrug reversal agent [28] and resembles 
quinidine in structural aspects. Both alkaloid molecules 
contain an aromatic heterocycle structure and a quinu- 
clidinyl moiety. Moreover, both organic bases have sim- 
ilar molecular weights (quinidine 324; ajmaline 326). In 
this study we have investigated the influence of quatemi- 
zation of the tertiary amine structure, resulting in the 
permanently cationic substrates APD-ajmalinium 
(M, = 407) and pentyl quinidinium (M, = 395), on the 
kinetic behavior in ATPaependent transport across the 
canalicular membrane of the hepatocyte. Several ines of 
evidence presented in this study strongly suggest that 
mdrl P-glycoprotein in canalicular membranes trans- 
ports not only quinidine but also the monoquatemary 
n-pentyl derivatives of ajmaline and quinidine: 
1. The photolabile ajmaline derivative labeled a canali- 
cular membrane protein in the molecular weight range 
of P-glycoprotein, as shown by comigration of the pho- 
toaffinity-labeled protein with the P-glycoprotein de- 
tected by the C219 antibody (Fig. 4). 
2. The ATP-dependent transport of the monoquater- 
nary cations in CMV was sensitive to inhibition by typi- 
cal multidrug reversal agents or known P-glycoprotein 
substrates at inhibitor concentrations which did not in- 
hibit the BSEC- or LTEC-mediated transport systems 
(Table 2) [21,23]. 
3. The uptake rates for the two permanently charged 
cations were similar in CMV prepared from normal Wis- 
tar rat liver and transport mutant liver (see section 3.1), 
which lacks functionally active LTEC but expresses 
P-glycoproteins [4,23]. 
The major portion of the P-glycoprotein detectable by 
the monoclonal antibody C219 in CMV from rat or 
mouse liver represents the mdr2 gene product [3] indicat- 
ing a relatively low expression of the mdrla and mdrlb 
Table 2 
Inhibitor specificity of the ATP-dependent ransport of amphiphilic 
cations across the canalicular membrane in comparison with the ATP- 
dependent bile salt (taurocholate) transport 
Substrate Inhibitor 
(20 PM) 
Rate % of control 
(pm01 . mg-’ . mm’) 
APD-ajmalinium control 180 + 18 
(5 FM) vanadate 90f 18 
quinidine 25 * 9 
pentyl 
quinidinium 9f7 
verapamil 27 + 2 
daunorubicin 20 2 9 
taurocholate 126 f 18 
Pentyl quinidinium control 122 f 6 
(1 PM) vanadate 13 + 5 
quinidine 21 f7 
pent yl 
quinidinium 6+5 
verapamil 12 +4 
daunorubicin 87 f 9 
taurocholate llOf2 
Taurocholate 
(5 PM) 
control 125 f 6 
quinidine 129+ 1 
pentyl 
quinidinium 114 f 3 
verapamil 134f6 
100 
492 10 
14+_ 5 
5f4 
15f 1 
11+5 
70+ 10 
100 
60 f 4 
17f6 
5+4 
lo? 3 
71&8 
90 f 2 
100 
103 + 9 
91 f2 
107 & 5 
Transport studies were performed as described in section 2. Values are 
expressed as the mean _+ S.E.M. from quadruplicate determinations. 
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genes in normal liver. However, highly efficient organic 
cation transport was demonstrated in this study by use 
of the amphiphilic quinuclidinium and ajmalinium com- 
pounds (Table 1). The efficiency of the ATP-dependent 
transport of pentyl quinidinium, calculated by the V,,,/ 
K,,, ratio, was 450 and thus in accordance with the ratios 
obtained for the physiological BSEC substrate taurocho- 
late (180), and for leukotriene C, (425) as the best 
substrate for LTEC, in contrast to the established P- 
glycoprotein substrate daunorubicin with a ratio of 14 
[6]. Pentyl quinidinium may, therefore, serve as a highly 
specific substrate in future studies defining physiological 
mdrl P-glycoprotein substrates. 
4.2. Implications for the mechanism of action of the 
multidrug export carrier 
Most P-glycoprotein substrates or inhibitors are weak 
bases or lipophilic uncharged molecules such as steroid 
hormones [1,29]. Passive diffusion of the uncharged 
basic substrate is faster than transport of the protonated 
form. The pH gradient across the membrane influences, 
therefore, drug accumulation. APD-ajmalinium, as a 
permanently charged cation, is not taken up by cells 
through passive diffusion but only by carrier-mediated 
transport [ 12,301. As pointed out by Gottesman and Pas- 
tan [l] mdrl P-glycoprotein may mediate both reduced 
influx of drugs into the cytosol and increased efflux out 
of the cell. A model has been proposed suggesting the 
removal of hydrophobic drugs directly out of the plasma 
membrane in a process comparable to the action of a 
‘hydrophobic vacuum cleaner’ [ 1,3 11. One may speculate 
that the mdrl gene product functions not only as a ‘hy- 
drophobic vacuum cleaner’ for hydrophobic basic drugs 
concentrated in the plasma membrane lipid bilayer, but 
also as a pump for more hydrophilic monoquaternary 
cations such as pentyl quinidinium or APD-ajmalinium. 
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